Search research articles
Contact Us
Filters
Showing results (111-120 of 145) with videos related to
Page
of 15
Sort By:
Internal Medicine Journal
|
January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Shirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 30, 2024
Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients
Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, et al.
The Lancet. Oncology
|
December 17, 2011
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Trappe, Stephan Oertel, Veronique Leblond, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
P Joy Ho, Elizabeth M Moore, Zoe K McQuilten, et al.
Blood Advances
|
May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
Peter Mollee, John Reynolds, Wojt Janowski, et al.
British Journal of Haematology
|
November 2, 2022
The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population
Joanne L C Tan, Cameron Wellard, Elizabeth M Moore, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 13, 2026
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups
Ghassan Zammar, Bradley Augustson, Elizabeth Moore, et al.
Internal Medicine Journal
|
March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia
Shirlene Sim, Anna Kalff, Gina Tuch, et al.
British Journal of Haematology
|
June 8, 2026
Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry
Kenneth J C Lim, Elham Ashrafi, Cameron Wellard, et al.
Leukemia & Lymphoma
|
October 13, 2017
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma
Ashleigh Scott, Nicholas Weber, Campbell Tiley, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 145) with videos related to
Sort By:
Page
of 15
Internal Medicine Journal
|
January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Shirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 30, 2024
Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients
Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, et al.
The Lancet. Oncology
|
December 17, 2011
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Trappe, Stephan Oertel, Veronique Leblond, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
P Joy Ho, Elizabeth M Moore, Zoe K McQuilten, et al.
Blood Advances
|
May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
Peter Mollee, John Reynolds, Wojt Janowski, et al.
British Journal of Haematology
|
November 2, 2022
The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population
Joanne L C Tan, Cameron Wellard, Elizabeth M Moore, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 13, 2026
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups
Ghassan Zammar, Bradley Augustson, Elizabeth Moore, et al.
Internal Medicine Journal
|
March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia
Shirlene Sim, Anna Kalff, Gina Tuch, et al.
British Journal of Haematology
|
June 8, 2026
Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry
Kenneth J C Lim, Elham Ashrafi, Cameron Wellard, et al.
Leukemia & Lymphoma
|
October 13, 2017
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma
Ashleigh Scott, Nicholas Weber, Campbell Tiley, et al.
Page
of 15